Remove Cardiovascular Disease Remove Lipid disorders Remove Risk Factors
article thumbnail

Cholesterol’s Star Role in Dementia Prevention: New Insights from the 2024 Lancet Dementia Report 

Cardiometabolic Health Congress

Updated with the latest research since the 2020 edition, this comprehensive report underscores the potential to prevent or significantly delay dementia by targeting modifiable risk factors. The report now identifies 14 modifiable risk factors for dementia.

article thumbnail

Creative Alliances in Cardiorenal Metabolic Management: A Game Changer (Part 1) 

Cardiometabolic Health Congress

Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. This ensures clear communication and identifies areas that need further explanation.

article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

The estimated relative risk reduction of MACE was 20% vs placebo (HR 0.80 [95% CI: 0.72, 0.90] p 1,2 The reduction of MACE with Wegovy was not impacted by age, sex, race, ethnicity, baseline BMI, or level of renal function impairment. Between 1999 and 2020, obesity-related cardiovascular disease deaths tripled in the U.S.,

Obesity 111